Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in ...
Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these ...
Adhering to the current guideline standard for intraoperative nodal assessment in resected non–small cell lung cancer (NSCLC) ...
In a trial, selected patients with early non-small cell lung cancer did not benefit from mediastinal lymph node dissection (LND). Mediastinal LND resulted in longer surgeries, increased bleeding, and ...
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
Study finds lower mortality rates associated with excisions of higher numbers of lymph nodes in patients with intermediate- and high-risk prostate cancer. Removal of greater numbers of lymph nodes ...
Through the use of preoperative axillary ultrasound (AUS), more patients with clinical node‑positive (cNI) breast cancer and ...
Extended dissection did not improve recurrence-free or overall survival, but it may have a bladder cancer-specific survival benefit possibly because it removes micrometastases. Extended lymph node ...
Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results